The typical patient that I would prescribe Epidyolex in is a patient who is known to have Dravet
syndrome or known to have LGS. The interesting thing about Epidiolex is that when tested it's
shown that although the mechanism of action, is not known, it does not seem to work of the
same principles, of the same mechanism, as a typical anti-epileptic drug. So we have a drug
with a novel mechanism of action, which has been shown in trials to be efficacious in a
substantial proportion of children with Dravet syndrome and Lennox-Gastaut syndrome, and
in conjunction with clobazam is shown to be effective. It’s an interesting addition to the
armamentarium.
When I introduce Epidiolex to a patient, the first thing that I say is that communication is key.
We will have to adjust or titrate the medication according to interactions and according to
side effects and according to efficacy. The other thing I’d like to say to my patients and is
what I say regularly to my patients now is that the viability will vary according to your fasting
status or eating status. Whichever it is, just be consistent about it.